Alzheimer Centers for Discovery of New Medicines (U54 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites U54 Cooperative Agreement applications aiming to establish multi-component Alzheimer Centers for the Discovery of New Medicines. The overarching purpose of this Centers program is to improve, diversify and reinvigorate the Alzheimer's disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will 1) design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as AMP-AD, and 2) initiate early stage drug discovery campaigns against the enabled targets.  


  • Letter of Intent Due Date(s): January 1, 2019
  • Application Due Date(s): February 1, 2019

RFA-AG-19-010 Expiration Date February 2, 2019

Agency Website



Amount Description

Application budgets may not exceed $5.25 million in direct costs per year. Budgets must reflect the actual needs of the proposed project.

The maximum period of support is 5 years.   

    Funding Type





    Engineering and Physical Sciences
    Environmental & Life Sciences
    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    February 1, 2019